HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: adc.2006.099499v1 92/2/F108    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harding, D R Articles by Montgomery, H E Search for Related Content PubMed PubMed Citation Articles by Harding, D R Articles by Montgomery, H E Topic Collections Relevant Article

Cognitive outcome and cyclo-oxygenase-2 gene (–765 G/C) variation in the preterm infant

¹ Peter Dunn Neonatal Intensive Care Unit, St Michael’s Hospital, Bristol, UK
² Cardiovascular Genetics, University College London, London, UK
³ Department of Clinical Science, University of Bristol, Southmead Hospital, Bristol, UK
⁴ School of Human Development, University of Nottingham, Nottingham, UK

Correspondence to:
Correspondence to:
D Harding
St Michael’s NICU, University of Bristol, D level, St Michael’s Hospital, Bristol BS2 8EG, UK; david.harding{at}bristol.ac.uk

Background: Cyclo-oxygenase (COX) inhibition by indomethacin does not result in an improvement in long-term neurocognitive outcome, despite reducing the incidence of both severe intraventricular haemorrhage and white matter injury visible on ultrasound. Diffuse brain injury after preterm birth may have inflammatory origins. These two points suggest that, in the preterm brain, COX inhibition may have a dominant proinflammatory or neuropathological role. The inducible form of the COX2 gene is polymorphic: the –765 C (rather than G) variant of the gene is associated with reduced COX2 activity.

Objective: To test the hypothesis that the C allele of COX2 is associated with worse neurodevelopmental outcomes after premature birth.

Outcomes: Cerebral palsy, disability, Griffith’s developmental quotient at 2 years and British Ability Scales-11 general cognitive ability and motor performance (movement assessment battery for children) at 5 years were compared with COX2 genotype.

Results: The C allele (GC 65 (31%), CC 3 (1%)) was independently associated with worse cognitive performance at 2 and 5 years: C allele mean (SEM) developmental quotient 92.7 (1.7), v GG 97.6 (1.5), p = 0.039; C allele mean (SEM) general cognitive ability, 94.3 (2.2) v GG 100.9 (1.7), p = 0.028.

Conclusion: An antineuropathological role for COX2 in the preterm brain may help account for the lack of effect of indomethacin treatment in improving neurocognitive outcomes in children born preterm, despite reported reduction in apparent brain injury.

Abbreviations: BAS, British Ability Scales-11; COX2, cyclo-oxygenase-2; GCA, general cognitive ability; IVH, intraventricular haemorrhage; PGE2, prostaglandin E₂; PVL, periventricular leucomalacia

Relevant Article

Fantoms

Martin Ward Platt
Arch. Dis. Child. Fetal Neonatal Ed. 2007 92: F79. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				D. Harding Impact of common genetic variation on neonatal disease and outcome Arch. Dis. Child. Fetal Neonatal Ed., September 1, 2007; 92(5): F408 - F413. [Abstract] [Full Text] [PDF]